Halozyme Therapeutics Inc (HALO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $11.43B
Last updated: Nov 17, 2026 at 11:06 AM ET
Halozyme Therapeutics Inc (HALO) Financials: Revenue, Profit and Cash Flow
Halozyme Therapeutics reported revenue of $1.40B for the fiscal year ended Dec 31, 2025, up 37.6% from the year before. That year, net income was $316.89M with a net margin of 22.7%, operating cash flow was $651.56M and free cash flow was $644.59M. The quarter ended Sep 30, 2026 had revenue of $492.97M and net income of $247.05M.
Revenue and Margins
The operating margin was 33.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $146.69M, a compound annual rate of 28.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.40B | +37.6% | 83.6% | 33.6% | 22.7% |
| Dec 2024 | $1.02B | +22.4% | 84.3% | 54.3% | 43.7% |
| Dec 2023 | $829.25M | +25.6% | 76.8% | 40.7% | 34.0% |
| Dec 2022 | $660.12M | +48.9% | 78.9% | 40.5% | 30.6% |
| Dec 2021 | $443.31M | +65.7% | 81.6% | 62.2% | 90.8% |
| Dec 2020 | $267.59M | +36.5% | 83.8% | 53.9% | 48.2% |
| Dec 2019 | $195.99M | +29.1% | 76.8% | -34.5% | -36.9% |
| Dec 2018 | $151.86M | -52.0% | 93.3% | -45.7% | -52.9% |
| Dec 2017 | $316.61M | +115.8% | 90.2% | 25.6% | 19.9% |
| Dec 2016 | $146.69M | N/A | 77.4% | -56.7% | -70.2% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 28.6% from the year before. In the quarter ended Sep 2026, net income rose 41.0% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.25M | $660.12M | $443.31M | $267.59M | $195.99M | $151.86M | $316.61M | $146.69M |
| Cost of revenue | $228.77M | $159.42M | $192.36M | $139.30M | $81.41M | $43.37M | $45.55M | $10.14M | $31.15M | $33.21M |
| Gross profit | $1.17B | $855.91M | $636.89M | $520.81M | $361.90M | $224.23M | $150.45M | $141.73M | $285.46M | $113.48M |
| Research and development | $366.38M | $79.05M | $76.36M | $66.61M | $35.67M | $34.24M | $140.80M | $150.25M | $150.64M | $150.84M |
| Operating income | $469.01M | $551.48M | $337.57M | $267.53M | $275.90M | $144.25M | -$67.61M | -$69.33M | $81.00M | -$83.21M |
| Net income | $316.89M | $444.09M | $281.59M | $202.13M | $402.71M | $129.09M | -$72.24M | -$80.33M | $62.97M | -$103.02M |
| EBITDA | $582.74M | $652.97M | $439.73M | $327.16M | $285.90M | $167.94M | -$56.54M | -$60.91M | $87.21M | -$63.39M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $492.97M | $481.00M | $376.71M | $451.77M | $354.26M | $325.72M | $264.86M | $298.01M | $290.08M | $231.35M | $195.88M | $230.04M |
| Gross profit | $410.50M | $401.83M | $297.47M | $373.00M | $299.02M | $279.36M | $216.46M | $255.95M | $240.66M | $191.75M | $167.55M | $177.74M |
| Operating income | $294.97M | $287.65M | $184.52M | -$92.89M | $217.92M | $202.44M | $141.53M | $175.50M | $163.20M | $117.23M | $95.54M | $101.03M |
| Net income | $247.05M | $229.91M | $150.05M | -$141.59M | $175.22M | $165.16M | $118.09M | $137.01M | $137.01M | $93.25M | $76.82M | $85.39M |
Balance Sheet
As of Dec 2025, total debt of $2.14B exceeded cash and equivalents by $2.01B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B | $579.92M | $565.87M | $440.25M | $519.95M | $261.51M |
| Current assets | $825.21M | $1.09B | $746.42M | $739.01M | $926.29M | $554.76M | $543.44M | $427.85M | $510.37M | $256.53M |
| Cash and equivalents | $133.82M | $115.85M | $118.37M | $234.19M | $118.72M | $147.70M | $120.18M | $57.94M | $168.74M | $66.76M |
| Total liabilities | $2.48B | $1.70B | $1.65B | $1.67B | $907.48M | $428.88M | $474.11M | $191.36M | $311.58M | $294.00M |
| Short-term debt | $0 | N/A | $6.58M | $13.33M | $89.42M | $397.23M | $19.54M | $91.51M | $77.21M | $17.39M |
| Long-term debt | $2.14B | $1.51B | $1.50B | $1.49B | $787.25M | $0 | $383.05M | $34.87M | $125.14M | $199.23M |
| Shareholder equity | $48.81M | $363.82M | $83.81M | $169.80M | $196.95M | $151.05M | $91.77M | $248.89M | $208.37M | -$32.48M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.47B | $2.58B | $2.67B | $2.53B | $2.22B | $2.05B | $2.20B | $2.06B | $2.12B | $1.97B | $1.84B | $1.73B |
| Total liabilities | $3.53B | $2.43B | $2.45B | $2.48B | $1.72B | $1.72B | $1.71B | $1.70B | $1.67B | $1.68B | $1.66B | $1.65B |
| Cash and equivalents | $1.03B | $163.14M | $309.75M | $133.82M | $419.67M | $61.86M | $176.33M | $115.85M | $154.32M | $187.86M | $164.63M | $118.37M |
| Shareholder equity | -$55.24M | $143.54M | $219.64M | $48.81M | $503.92M | $332.75M | $482.27M | $363.82M | $452.70M | $289.42M | $177.81M | $83.81M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.9% of operating cash flow. Share repurchases came to 53.1% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $651.56M | $479.06M | $388.57M | $240.11M | $299.44M | $55.45M | -$85.42M | -$49.50M | $134.05M | -$50.38M |
| Capital expenditures | $6.97M | $10.70M | $15.29M | $4.81M | $1.46M | $2.50M | $4.04M | $4.66M | $1.54M | $3.14M |
| Free cash flow | $644.59M | $468.37M | $373.28M | $235.30M | $297.98M | $52.95M | -$89.46M | -$54.16M | $132.51M | -$53.52M |
| Dividends paid | N/A | N/A | $13.48M | N/A | $12.54M | $63.39M | $14.22M | N/A | $0 | $0 |
| Share repurchases | $342.37M | $250.00M | $402.38M | $200.00M | $350.06M | $150.12M | $200.00M | $0 | $0 | N/A |
| Investing cash flow | -$545.81M | -$262.72M | -$96.91M | -$487.00M | -$406.29M | $78.35M | -$5.55M | $2.49M | -$163.73M | -$76.77M |
| Financing cash flow | -$85.17M | -$218.86M | -$407.99M | $362.37M | $77.86M | -$106.28M | $153.22M | -$63.80M | $131.66M | $150.62M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $258.27M | $240.89M | $180.08M | $219.03M | $178.60M | $99.71M | $154.22M | $178.47M | $115.38M | $55.79M | $129.43M | $102.35M |
| Capital expenditures | $3.05M | $4.17M | $3.74M | $1.43M | $3.03M | $1.56M | $950.00K | $3.05M | $1.52M | $2.58M | $3.54M | $2.60M |
| Free cash flow | $255.22M | $236.72M | $176.34M | $217.60M | $175.57M | $98.15M | $153.27M | $175.41M | $113.86M | $53.21M | $125.88M | $99.76M |
Frequently Asked Questions About HALO
What is Halozyme Therapeutics' annual revenue?
Halozyme Therapeutics reported revenue of $1.40B for the fiscal year ended Dec 31, 2025.
How fast is Halozyme Therapeutics' revenue growing?
Revenue was up 37.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 28.4%.
Is Halozyme Therapeutics profitable?
Yes. Halozyme Therapeutics reported net income of $316.89M for the fiscal year ended Dec 31, 2025, with a net margin of 22.7%.
How much free cash flow does HALO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $651.56M minus capital expenditures of $6.97M produced free cash flow of $644.59M.
How much debt does Halozyme Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $2.14B, short-term debt of $0 and cash and equivalents of $133.82M.
HALO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors